RxDoctor Payments Data

Sharon Rose Yap Palomo, MD

Family Medicine · Wichita Falls, TXNPI 1871560342

Payments from drug & device makers

$7,446in general payments, 2019–2025

Across 511 payments — averaging $14.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$1K
  • AbbVie$838
  • Lilly USA, LLC$682
  • GSK$539
  • Merck$458
  • plus $3K from 25 others

What the payments were for

  • Food & beverage$7,412100%
  • Education$340%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,446 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$204,734
Medicare patients
291
Services billed
5,989

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide153$157,444
MounjaroTirzepatide57$57,721
JardianceEmpagliflozin55$52,769
Tresiba Flextouch U-200Insulin Degludec42$42,576
EliquisApixaban35$29,777
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$18,874
Janumet XrSitagliptin Phos/Metformin Hcl23$17,890
Breo ElliptaFluticasone/Vilanterol27$13,092
FarxigaDapagliflozin Propanediol22$12,658
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr23$10,671
VascepaIcosapent Ethyl14$6,299
SynthroidLevothyroxine Sodium52$3,718
Icosapent Ethyl16$3,039
PaxlovidNirmatrelvir/Ritonavir17$2,858
Levothyroxine Sodium243$2,737

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,315$157,444153 claims
Lilly USA, LLCMounjaro$682$57,72157 claims
Boehringer IngelheimJardiance$332$52,76955 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$539$42,63874 claims
PfizerEliquis, Paxlovid$133$32,63552 claims
MerckJanumet Xr$458$17,89023 claims
AstraZenecaFarxiga$1,105$12,65822 claims
AbbVieSynthroid$838$3,71852 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Wichita Falls

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →